van Ommen-Nijhof, Annemiek http://orcid.org/0000-0002-1797-1060
Jacobse, Judy N. http://orcid.org/0000-0001-9214-5263
Steggink, Lars C. http://orcid.org/0000-0001-8955-8702
Lefrandt, Joop D. http://orcid.org/0000-0001-7059-3882
Gietema, Jourik A. http://orcid.org/0000-0003-0629-7354
van Leeuwen, Flora E. http://orcid.org/0000-0002-5871-1484
Schaapveld, Michael http://orcid.org/0000-0003-4390-7182
Sonke, Gabe S. http://orcid.org/0000-0001-8088-9628
Clinical trials referenced in this document:
Documents that mention this clinical trial
Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors
https://doi.org/10.1007/s10549-022-06714-0
Funding for this research was provided by:
KWF Kankerbestrijding (2012.WO39.C143)
Article History
Received: 6 May 2022
Accepted: 14 August 2022
First Online: 1 October 2022
Declarations
:
: Jourik Gietema reports institutional research support from Roche, Abbvie and Siemens. Gabe Sonke reports institutional research support from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen and consultancy fees paid to the institution from Biovica and Seagen. Annemiek van Ommen-Nijhof, Lars Steggink, Judy Jacobse, Joop Lefrandt, Flora van Leeuwen and Michael Schaapveld report no competing interests.
: The institutional review board of the NKI-AVL approved the study and it is registered with ClinicalTrials.gov, identifier NCT02485626. The study was carried out according to the principles of the Declaration of Helsinki.
: All participants provided written informed consent prior to enrolment in the study.